Literature DB >> 26352816

Cannabinoids in the Treatment of Epilepsy.

Daniel Friedman, Orrin Devinsky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26352816     DOI: 10.1056/NEJMra1407304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  69 in total

Review 1.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

Review 2.  Cannabinoids in Pediatrics.

Authors:  Christopher T Campbell; Marjorie Shaw Phillips; Kalen Manasco
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

3.  Cannabidiol and Serum Antiepileptic Drug Levels: The ABCs of CBD With AEDs.

Authors:  Bernard S Chang
Journal:  Epilepsy Curr       Date:  2018 Jan-Feb       Impact factor: 7.500

4.  Pharmacy Student Knowledge, Confidence and Attitudes Toward Medical Cannabis and Curricular Coverage.

Authors:  Frank J Caligiuri; Erin E Ulrich; Kelli Jo Welter
Journal:  Am J Pharm Educ       Date:  2018-06       Impact factor: 2.047

Review 5.  Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.

Authors:  Martin J Brodie
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

7.  Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Authors:  Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Pharmacol Res       Date:  2017-08-23       Impact factor: 7.658

8.  Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats.

Authors:  Megan N Huizenga; Patrick A Forcelli
Journal:  Neurotox Res       Date:  2018-08-24       Impact factor: 3.911

Review 9.  Recent Advances in the Drug Treatment of Dravet Syndrome.

Authors:  Elaine C Wirrell; Rima Nabbout
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

10.  Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'.

Authors:  Paul L Prather
Journal:  Drug Metab Rev       Date:  2018-01-30       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.